{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:09:09Z","timestamp":1766048949858},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2018,4,21]],"date-time":"2018-04-21T00:00:00Z","timestamp":1524268800000},"content-version":"vor","delay-in-days":110,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,1]]},"DOI":"10.1093\/jtm\/tay026","type":"journal-article","created":{"date-parts":[[2018,3,17]],"date-time":"2018-03-17T20:08:23Z","timestamp":1521317303000},"source":"Crossref","is-referenced-by-count":4,"title":["Adverse events in vaccinations for travelers \u2013 a 1-year prospective survey in a travel clinic in Germany"],"prefix":"10.1093","volume":"25","author":[{"given":"G\u00fcnther","family":"Slesak","sequence":"first","affiliation":[{"name":"Tropical Medicine Department, Tropenklinik Paul-Lechler-Krankenhaus, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Fleck","sequence":"additional","affiliation":[{"name":"Tropical Medicine Department, Tropenklinik Paul-Lechler-Krankenhaus, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Scherbaum","sequence":"additional","affiliation":[{"name":"Tropical Medicine Department, Tropenklinik Paul-Lechler-Krankenhaus, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Blumenstock","sequence":"additional","affiliation":[{"name":"Institute of Clinical Epidemiology and Applied Biometry, Eberhard Karls University, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Sch\u00e4fer","sequence":"additional","affiliation":[{"name":"Tropical Medicine Department, Tropenklinik Paul-Lechler-Krankenhaus, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,4,21]]},"reference":[{"key":"key\n\t\t\t\t20180925002231_tay026C1","first-page":"12","article-title":"Daten zur Pharmakovigilanz von Impfstoffen aus dem Jahr 2014","author":"Mentzer","year":"2016","journal-title":"Bulletin zur Arzneimittelsicherheit"},{"key":"key\n\t\t\t\t20180925002231_tay026C2","doi-asserted-by":"crossref","first-page":"e0004846","DOI":"10.1371\/journal.pntd.0004846","article-title":"Post-marketing surveillance of human rabies diploid cell vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990\u20132015","volume":"10","author":"Moro","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"key\n\t\t\t\t20180925002231_tay026C3","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180925002231_tay026C4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/v8110279","article-title":"Rabies control and treatment: from prophylaxis to strategies with curative potential","volume":"8","author":"Zhu","year":"2016","journal-title":"Viruses"},{"key":"key\n\t\t\t\t20180925002231_tay026C5","first-page":"17","article-title":"Parental vaccine refusal in Wisconsin: a case-control study","volume":"108","author":"Salmon","year":"2009","journal-title":"WMJ"},{"key":"key\n\t\t\t\t20180925002231_tay026C6","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.mayocp.2015.09.006","article-title":"Vaccine hesitancy","volume":"90","author":"Jacobson","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"key\n\t\t\t\t20180925002231_tay026C7","first-page":"30","article-title":"Anaphylaxie nach Impfung von Kindern und Jugendlichen in Deutschland","volume":"2","author":"Oberle","year":"2016","journal-title":"Bulletin zur Arzneimittelsicherheit"},{"key":"key\n\t\t\t\t20180925002231_tay026C8","author":"FDA","year":"2016"},{"key":"key\n\t\t\t\t20180925002231_tay026C9","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)","year":"1994"},{"key":"key\n\t\t\t\t20180925002231_tay026C10","first-page":"1404","article-title":"[Adverse drug reactions following immunization in Germany pursuant to the German Infection Protection Act and the German Medicinal Products Act from January 1, 2004 to December 31, 2005]","volume":"50","author":"Weisser","year":"2007","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"key\n\t\t\t\t20180925002231_tay026C11","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0264-410X(00)00342-X","article-title":"Purified chick embryo cell culture rabies vaccine: interchangeability with human diploid cell culture rabies vaccine and comparison of one versus two-dose post-exposure booster regimen for previously immunized persons","volume":"19","author":"Briggs","year":"2008","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180925002231_tay026C12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1586\/14760584.2015.1011134","article-title":"30 Years of rabies vaccination with Rabipur: a summary of clinical data and global experience","volume":"14","author":"Giesen","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"key\n\t\t\t\t20180925002231_tay026C13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.tmaid.2015.05.008","article-title":"Evaluation of rabies immunogenicity and tolerability following a purified chick embryo cell rabies vaccine administered concomitantly with a Japanese encephalitis vaccine","volume":"13","author":"Jelinek","year":"2015","journal-title":"Travel Med Infect Dis"},{"key":"key\n\t\t\t\t20180925002231_tay026C14","first-page":"1","article-title":"Human rabies prevention\u2014United States, 2008: recommendations of the Advisory Committee on Immunization Practices","volume":"57","author":"Manning","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"key\n\t\t\t\t20180925002231_tay026C15","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/0264-410X(87)90102-2","article-title":"Pre-exposure studies with purified chick embryo cell culture rabies vaccine and human diploid cell vaccine: serological and clinical responses in man","volume":"5","author":"Nicholson","year":"1987","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180925002231_tay026C16","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1080\/21645515.2015.1048938","article-title":"Comparison of safety and immunogenicity of 2 WHO prequalified rabies vaccines administered by one week, 4 site intra dermal regimen (4-4-4-0-0) in animal bite cases","volume":"11","author":"Narayana","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"key\n\t\t\t\t20180925002231_tay026C17","doi-asserted-by":"crossref","first-page":"e5049","DOI":"10.1097\/MD.0000000000005049","article-title":"Safety comparison of four types of rabies vaccines in patients with WHO category II animal exposure: an observation based on different age groups","volume":"95","author":"Peng","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"key\n\t\t\t\t20180925002231_tay026C18","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0091-6749(87)80278-6","article-title":"The role of specific IgE and beta-propiolactone in reactions resulting from booster doses of human diploid cell rabies vaccine","volume":"80","author":"Anderson","year":"1987","journal-title":"J Allergy Clin Immunol"},{"key":"key\n\t\t\t\t20180925002231_tay026C19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0264-410X(86)90096-4","article-title":"Immune complex-like disease in 23 persons following a booster dose of rabies human diploid cell vaccine","volume":"4","author":"Dreesen","year":"1986","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180925002231_tay026C20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.tmaid.2007.07.004","article-title":"Preventing rabies with the Verorab vaccine: 1985\u20132005 twenty years of clinical experience","volume":"5","author":"Toovey","year":"2007","journal-title":"Travel Med Infect Dis"},{"key":"key\n\t\t\t\t20180925002231_tay026C21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2310\/7060.2004.19001","article-title":"Safety and immunogenicity of a new chromatographically purified rabies vaccine in comparison to the human diploid cell vaccine","volume":"11","author":"Arora","year":"2004","journal-title":"J Travel Med"},{"key":"key\n\t\t\t\t20180925002231_tay026C22","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1016\/j.vaccine.2007.02.075","article-title":"Safety review of the purified chick embryo cell rabies vaccine: data from the Vaccine Adverse Event Reporting System (VAERS), 1997\u20132005","volume":"25","author":"Dobardzic","year":"2007","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180925002231_tay026C23","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taw045","article-title":"Adverse event reports following yellow fever vaccination, 2007\u201313","volume":"23","author":"Lindsey","year":"2016","journal-title":"J Travel Med"},{"key":"key\n\t\t\t\t20180925002231_tay026C24","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/14760584.2016.1180250","article-title":"Yellow fever vaccine: worthy friend or stealthy foe?","volume":"15","author":"Seligman","year":"2016","journal-title":"Expert Rev Vaccine"},{"key":"key\n\t\t\t\t20180925002231_tay026C25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4269\/ajtmh.2005.72.339","article-title":"Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial","volume":"72","author":"Pfister","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"key\n\t\t\t\t20180925002231_tay026C26","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.4269\/ajtmh.1999.60.1045","article-title":"Comparison of the immunogenicity and safety of two 17D yellow fever vaccines","volume":"60","author":"Lang","year":"1999","journal-title":"Am J Trop Med Hyg"},{"key":"key\n\t\t\t\t20180925002231_tay026C27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4269\/ajtmh.2005.72.189","article-title":"Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru","volume":"72","author":"Belmusto-Worn","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"key\n\t\t\t\t20180925002231_tay026C28","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.vaccine.2015.03.069","article-title":"Observational study on immune response to yellow fever and measles vaccines in 9 to 15-month old children. Is it necessary to wait 4 weeks between two live attenuated vaccines?","volume":"11","author":"Michel","year":"2015","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180925002231_tay026C29","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.vaccine.2014.12.024","article-title":"Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged \u226550 years: a randomised non-inferiority clinical trial","volume":"33","author":"Diez-Domingo","year":"2015","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180925002231_tay026C30","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00431-010-1142-6","article-title":"Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella-varicella vaccine to children aged 11\u201321 months","volume":"169","author":"Knuf","year":"2010","journal-title":"Eur J Pediatr"},{"key":"key\n\t\t\t\t20180925002231_tay026C31","first-page":"1825","article-title":"Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix\u2122): a review of its immunogenicity, safety, co-administration, and antibody persistence","volume":"12","author":"Assaf-Casals","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"key\n\t\t\t\t20180925002231_tay026C32","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.tmaid.2014.04.011","article-title":"Co-administration of a meningococcal glycoconjugate ACWY vaccine with travel vaccines: a randomized, open-label, multi-center study","volume":"12","author":"Alberer","year":"2014","journal-title":"Travel Med Infect Dis"},{"key":"key\n\t\t\t\t20180925002231_tay026C33","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2310\/7060.2003.31690","article-title":"Jelinek. Tolerability of multiple vaccinations in travel medicine","volume":"10","author":"B\u00f6rner","year":"2003","journal-title":"J Travel Med"},{"key":"key\n\t\t\t\t20180925002231_tay026C34","first-page":"taw011","article-title":"One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series","volume":"23","author":"Cramer","year":"2016","journal-title":"J Travel Med"},{"key":"key\n\t\t\t\t20180925002231_tay026C35","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.vaccine.2013.12.034","article-title":"Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants","volume":"32","author":"Abdelnour","year":"2014","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180925002231_tay026C36","author":"WHO","year":"2017"},{"key":"key\n\t\t\t\t20180925002231_tay026C37","doi-asserted-by":"crossref","first-page":"taw012","DOI":"10.1093\/jtm\/taw012","article-title":"Comparative study of adverse events after yellow fever vaccination between elderly and non-elderly travellers: questionnaire survey in Japan over a 1-year period","volume":"23","author":"Tanizaki","year":"2016","journal-title":"J Travel Med"},{"key":"key\n\t\t\t\t20180925002231_tay026C38","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4161\/hv.22714","article-title":"Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more","volume":"9","author":"Miyaji","year":"2013","journal-title":"Hum Vaccin Immunother"}],"container-title":["Journal of Travel Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jtm\/article-pdf\/25\/1\/tay026\/25833895\/tay026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T01:53:31Z","timestamp":1570931611000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jtm\/article\/doi\/10.1093\/jtm\/tay026\/4980870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,1]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,4,21]]},"published-print":{"date-parts":[[2018,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jtm\/tay026","relation":{},"ISSN":["1708-8305"],"issn-type":[{"value":"1708-8305","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018]]},"published":{"date-parts":[[2018,1,1]]}}}